Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174687 · ClinicalTrials.gov registry record · Phase 2
SGLT2 Inhibitors in Geographic Atrophy
A Phase 2 study of Eye Diseases and Geographic Atrophy, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT07174687 is a Phase 2 study of Eye Diseases and Geographic Atrophy that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 70 participants, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07174687, a Phase 2 study of Eye Diseases and Geographic Atrophy, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.
Conditions Studied
Interventions
- DRUG Dapagliflozin
- OTHER Matching Placebo
Study Locations (1)
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07174687
The ClinicalTrials.gov registry entry for NCT07174687 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Eye Diseases appearing as the primary indexed condition, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT07174687 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT07174687 about?
NCT07174687 is a clinical study titled "SGLT2 Inhibitors in Geographic Atrophy". AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, a...
What is the current status of trial NCT07174687?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-12-02. Estimated completion is 2028-06.
What conditions does trial NCT07174687 study?
This clinical trial studies the following conditions: Eye Diseases, Geographic Atrophy, Retinal Degeneration, Retinal Diseases, Pathological Conditions, Anatomical.
What interventions are being tested in trial NCT07174687?
The interventions under investigation include: Dapagliflozin (DRUG), Matching Placebo (OTHER).
Who is sponsoring clinical trial NCT07174687?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174687 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
COMPLETED · Phase 2
-
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.